DEXILANT SOLUTAB
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Approved
Jan 2016
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEXILANT SOLUTAB is an orally disintegrating delayed-release tablet formulation of dexlansoprazole, a proton pump inhibitor (PPI) used to treat acid-reflux conditions. The mechanism involves irreversible inhibition of gastric H+/K+-ATPase, suppressing gastric acid secretion. This formulation addresses patient convenience by enabling administration without water.
LOE Approaching2.5 years to LOE
With LOE approaching in 2.5 years and moderate competitive pressure (score: 15), brand teams are shifting focus toward lifecycle extension strategies and defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on DEXILANT SOLUTAB at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.